Parametric-time coherent states in a superintegrable Coulomb-type system
Physica Scripta · 25.09.2026 · 101 (38) · 385105
DOI: 10.1088/1402-4896/aea5fa ↗Kurz gefasst
Fachartikel in der Zeitschrift Physica Scripta, online erschienen am 22.09.2026. Verfasst von Nalan Kandirmaz. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this work, we constructed parametric-time coherent states (CS) for a superintegrable Coulomb-type system using the Feynman path integral formalism. This system corresponds to a deformation-dependent extension of the Kepler–Coulomb potential and exhibits maximal superintegrability governed by an indexing parameter. Using the Duru–Kleinert transformation, we mapped the problem onto an effective four-dimensional isotropic harmonic oscillator in parametric time. This transformation allowed the explicit derivation of the propagator, energy spectrum, and coherent-state wave functions while preserving the underlying symmetry structure. The resulting parametric-time CS satisfied the minimum uncertainty relation in the unsqueezed limit and exhibited non-trivial time-dependent squeezing behaviour. We showed that the deformation parameter controlled both the effective spectral scale and the redistribution of quantum fluctuations, leading to deformation-dependent noise suppression.
Zitieren
APA
Kandirmaz, N. (2026). Parametric-time coherent states in a superintegrable Coulomb-type system. Physica Scripta, 101(38), 385105. https://doi.org/10.1088/1402-4896/aea5fa
Vancouver
Kandirmaz N. Parametric-time coherent states in a superintegrable Coulomb-type system. Physica Scripta. 2026;101(38):385105. doi:10.1088/1402-4896/aea5fa
BibTeX
@article{Kandirmaz2026,
author = {Kandirmaz, Nalan},
title = {Parametric-time coherent states in a superintegrable Coulomb-type system},
journal = {Physica Scripta},
year = {2026},
volume = {101},
number = {38},
pages = {385105},
doi = {10.1088/1402-4896/aea5fa}
}
EUVIMED